1Jul 2019

Keeping up with the Pharmaceutical Industry in Asia

July 1st, 2019|Categories: Asia-Pacific Pharma Market, Business, Clinical Trials|Tags: , , , , , , , |0 Comments

Keeping up with pharmaceutical landscape around the world, especially in Asia, is essential in today’s market. Here are some of the biggest news stories emerging from Asian countries that are making big strides in drug development. China: Recently, China has been quickly advancing in the process of approving of [...]

10Oct 2018

China Reshaping the Clinical Trial Pipeline

October 10th, 2018|Categories: Asia-Pacific Pharma Market, Clinical Trials|Tags: , |0 Comments

Finally, the data is in here at OZMOSI, and we can start tracking and reporting on the clinical development expected to come out of China.  Gone are the days of developing drugs only in the US and then watching them slowly make their way to the rest of the world. [...]

27Sep 2018

The Clinical Trial Powershift

September 27th, 2018|Categories: Clinical Trials|Tags: , , , , |0 Comments

Pharmaceutical companies are being pushed aside when it comes to who is driving clinical outcomes. Despite the growing number of industry trials year over year, the pharmaceutical industry is taking a back seat to the even faster growing hospital groups and universities in the same space.  Looking back to the [...]

16Nov 2017

ELI LILLY in the Diabetes Market

November 16th, 2017|Categories: Business, Chronic Disease, Diabetes|0 Comments

For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio of insulins continues to drive significant revenue with over [...]

19Oct 2017


October 19th, 2017|Categories: Chronic Disease, Diabetes|Tags: , , |0 Comments

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1 combination product Xultophy®,  which is expected to reach $1.2 [...]

28Aug 2017


August 28th, 2017|Categories: Business, Data Analytics, Diabetes|0 Comments

Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class. But Merck has no plans of stopping there with four different products [...]